Headquartered in Gaithersburg, Maryland, Novavax is a late-stage biotechnology company that promotes improved global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis.
Novavax has more than a decade of experience contending with some of the world’s most devastating diseases, including seasonal influenza, RSV, Ebola, MERS, and SARS. It is preparing to enter phase III clinical trials with NVX-CoV2373, a leading COVID-19 vaccine candidate. As part of the US government's Warp Speed initiative, large scale manufacturing capacity is already being established for NVX-CoV2373 leveraging a global network of CMOs and partnerships.
Driven by its COVID-19 vaccine development and manufacturing data management complexities, Novavax wanted to harden its data infrastructure, discontinue wide scale use of Excel for batch/process/product data management, and accelerate data sharing among a large external network.